Wall Street Zen Upgrades Autonomix Medical (NASDAQ:AMIX) to Hold

Autonomix Medical (NASDAQ:AMIX – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a research report on Monday, October 26th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $42.00.

View Our Latest Stock Analysis on AMIX

Autonomix Medical Stock Performance

AMIX stock opened at $1.37 on Friday. The stock has a market capitalization of $1.33 million, a price-to-earnings ratio of -0.03 and a beta of -0.70. Autonomix Medical has a 1 year low of $1.30 and a 1 year high of $32.55. The stock’s fifty day moving average is $3.06 and its two-hundred day moving average is $6.40.

Autonomix Medical (NASDAQ:AMIX – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($2.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.62) by $0.11. As a group, analysts predict that Autonomix Medical will post -20.17 EPS for the current fiscal year.

Autonomix Medical Company Profile

(Get Free Report)

Autonomix Medical, Inc. is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures. Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.

See Also

Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.